1801 Augustine Cut-Off
About Incyte Corporation
Drug Discovery & Development
Since we began our drug-discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.
Incyte has an exceptional team of drug discovery and development scientists led by distinguished executives with proven records of success and many scientific and clinical achievements. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success. We have a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations. Our therapeutic focus is primarily on oncology.
One Molecule at a Time
450 articles with Incyte Corporation
With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.
The approval of Jakafi marks the first approved treatment for this indication in the United States.
For young people looking to find a career path, the pharmaceutical industry is a good one to go into, especially if salary is a major concern.
FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
Jakafi is the first and only FDA-approved treatment for patients with steroid-refractory acute graft-versus-host disease (GVHD)
Incyte Corporation announced that it will present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm / 5:00 pm in Rancho Palos Verdes.
Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology
Investor conference call and webcast scheduled for Monday, June 17 at 8 a.m. EDT
Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA
Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.
May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look.
Incyte Corporation announced that it will present at the following investor conferences during the month of May
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019
Scheduled its first quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2019.
The MPN community is encouraged to participate in awareness initiatives and access new resources at VoicesofMPN.com.
Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019
The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.
Incyte Corporation announced that it will present at the following investor conferences during the month of March:
Two of the three drugs that were up for review in mid- to late-February received much earlier approval in December 21, the day before the federal government shutdown. The shutdown ended on January 25, 2019.
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company’s development portfolio.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 14, 2019.
Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease
Incyte Corporation today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD).